Councilor Viewpoints

Add a description of this content here

test

Choosing the most appropriate first line biologic

Biologics 2020

Richard Warren, BSc, MBChB, FRCP, PhD | United Kingdom

How to select a systemic treatment for your patient

Biologics 2020

Craig Leonardi, MD | United States

Challenging case: How to switch to the most optimal treatment

Biologics, Challenging case 2020

Craig Leonardi, MD | United States

Management of psoriasis with biologics during the COVID-19 pandemic – Italian

Biologics, COVID-19, Take Ten 2020

Paolo Gisondi, MD | Italy

Biologics: Modification strategies

Biologics, Take Ten 2021

Marc Bourcier, MD, FRCPC | Canada

Biologics: Dose optimization

Biologics, Take Ten 2021

Marc Bourcier, MD, FRCPC | Canada

Caso Clínico 2: Psoriasis paradojal inducida por anti-TNF

Biologics, Challenging case, Spanish 2021

Romina Contreras, MD | Paraguay

Latest news

Dermavant Announces FDA Approval for VTAMA® (Tapinarof) Cream

May 26, 2022

Dermavant announced the FDA approval for VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults. This is the first topical novel chemical entity launched for psoriasis in the U.S. in 25 years.

Bristol Myers Squibb (BMS) Announces New Two-Year Deucravacitinib Data

May 16, 2022

Bristol Myers Squibb (BMS) announced new two-year data that reinforces the durable efficacy and consistent safety profile of Deucravacitinib when used to treat moderate to severe plaque psoriasis.

Commentary: Vaccine Hesitancy and Access to Psoriasis Care in the COVID-19 Pandemic

May 11, 2022

IPC Councilor, Ulrich Mrowietz, MD, shares his expert opinion on Cook et al (Br J Dermatol 2022 (online first)) report on the interruption of psoriasis care during the COVID-19 pandemic and vaccine hesitancy in patients with psoriasis.

New Corporate Member

May 03, 2022

IPC is pleased to welcome AnaptysBio as a Bronze Level Corporate Member!

More News

Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others